NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022

Thomas W. Flaig(Janssen (Belgium)), Philippe E. Spiess(Janssen (Belgium)), Michael Abern(Janssen (Belgium)), Neeraj Agarwal(Janssen (Belgium)), Rick Bangs(Janssen (Belgium)), Stephen A. Boorjian(Janssen (Belgium)), Mark K. Buyyounouski(Janssen (Belgium)), Kevin Chan(City Of Hope National Medical Center), Sam S. Chang(Janssen (Belgium)), Terence W. Friedlander(Janssen (Belgium)), Richard E. Greenberg(Fox Chase Cancer Center), Khurshid A. Guru(Janssen (Belgium)), Harry W. Herr(Memorial Sloan Kettering Cancer Center), Jean Hoffman‐Censits(Janssen (Belgium)), Amar U. Kishan(Janssen (Belgium)), Shilajit Kundu(Janssen (Belgium)), Subodh M. Lele(Janssen (Belgium)), Ronac Mamtani(Janssen (Belgium)), Vitaly Margulis(Janssen (Belgium)), Omar Y. Mian(Cleveland Clinic), Jeff M. Michalski(Barnes-Jewish Hospital), Jeffrey S. Montgomery(University of Michigan), Lakshminarayanan Nandagopal(University of Colorado Cancer Center), Lance C. Pagliaro(Janssen (Belgium)), Mamta Parikh(UC Davis Comprehensive Cancer Center), Anthony Patterson(St. Jude Children's Research Hospital), Elizabeth R. Plimack(Fox Chase Cancer Center), Kamal S. Pohar(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Mark A. Preston(Dana-Farber Brigham Cancer Center), Kyle A. Richards(University of Wisconsin Carbone Cancer Center), Wade J. Sexton(Janssen (Belgium)), Arlene O. Siefker‐Radtke(The University of Texas MD Anderson Cancer Center), Matthew K. Tollefson(Janssen (Belgium)), Jonathan D. Tward(Janssen (Belgium)), Jonathan L. Wright(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Mary A. Dwyer(National Comprehensive Cancer Network), Carly J. Cassara(National Comprehensive Cancer Network), Lisa A. Gurski(National Comprehensive Cancer Network)
Journal of the National Comprehensive Cancer Network
August 1, 2022
10.6004/jnccn.2022.0041
Cited by 301Open Access
Full Text

Abstract

The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary carcinoma of the urethra). These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non-muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non-muscle invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody-drug conjugates for metastatic bladder cancer.

Related Papers

No related papers found

Powered by citation graph analysis